These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 11042581)

  • 1. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
    Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
    Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
    Bonnekoh B; Schulz M; Franke I; Gollnick H
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of primary cutaneous B-cell lymphoma with rituximab.
    Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
    J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
    Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
    Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
    Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab.
    Nagasaka A; Matsue H; Kawamura T; Kanzaki M; Inozume T; Nakamura Y; Shimzu A; Shibagaki N; Yanagi M; Shimada S
    J Dermatol; 2006 May; 33(5):377-9. PubMed ID: 16700675
    [No Abstract]   [Full Text] [Related]  

  • 17. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
    Nakai S; Masaki T; Shintani T; Deguchi A; Kimura Y; Himoto T; Kurokohchi K; Watanabe S; Kuriyama S
    Oncol Rep; 2005 Jun; 13(6):1065-8. PubMed ID: 15870922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
    Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
    Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
    Gamo R; Calzado L; Pinedo F; López-Estebaranz JL
    Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
    Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.